큐리언트
Financials
Valuation Metrics
큐리언트's Market Cap is ₩9603B. At end of 2025 it was ₩1.1T. Ranked #311 of 2,433 in KR market (top 13%), #83 of 1,647 on KOSDAQ (top 5%), #36 of 233 in Pharmaceuticals, Biotechnology & Life Sciences (top 15%) by Market Cap.
Investment Metrics(as of 2026-08-14)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 960.32B KRW | KR#311/2,433 Sec#36/233 |
| Revenue | 7.00B KRW | KR#2,317/2,433 Sec#185/233 |
| Net Income | -32.89B KRW | KR—/2,433 Sec—/233 |
| Total Assets | 61.99B KRW | KR#2,075/2,433 Sec#181/233 |
| Net Assets | 39.19B KRW | KR#2,047/2,433 Sec#179/233 |
| Employees | 33 | KR#2,156/2,433 Sec#197/233 |
| Value | ||
| P/B | 24.50x | KR#2,403/2,433 Sec#224/233 |
| P/S | 137.11x | KR#2,403/2,433 Sec#215/233 |
| FCF Yield | -2.99% | KR—/2,433 Sec—/233 |
| Profitability | ||
| ROE | -83.93% | KR#2,332/2,433 Sec#217/233 |
| ROA | -53.06% | KR#2,365/2,433 Sec#219/233 |
| Op. Margin | -438.41% | KR#2,369/2,433 Sec#205/233 |
| Revenue Growth | 1.12% | KR#1,476/2,433 Sec#136/233 |
| Financial Health | ||
| Debt Ratio | 58.18% | KR#1,077/2,433 Sec#127/233 |
| Total Debt | 9.42B KRW | KR#1,626/2,433 Sec#145/233 |
| FCF | -28.73B KRW | KR#1,986/2,433 Sec#191/233 |
| Cash | 21.04B KRW | KR#1,203/2,433 Sec#83/233 |
| Current Ratio | 19.26x | KR#25/2,433 Sec#11/233 |
| Performance | ||
| 1Y Return | 134.65% | KR#109/2,433 Sec#10/233 |
| 1M Return | 38.45% | KR#92/2,433 Sec#11/233 |
| From 52W High | -59.30% | KR#1,860/2,433 Sec#151/233 |
| 1Y MDD | -70.83% | KR#1,986/2,433 Sec#174/233 |
| Trading | ||
| Volume | 170,239 shares | KR#689/2,433 Sec#50/233 |
| Trading Value | 4.38B KRW | KR#428/2,433 Sec#40/233 |
| Foreign Own. | 5.66% | KR#724/2,433 Sec#68/233 |
| Per Share | ||
| EPS | -877 KRW | KR—/2,433 Sec—/233 |
| BPS | 1,045 KRW | KR#2,278/2,433 Sec#204/233 |
Company Info
QURIENT was established in 2008 to commercialize research from the Korea Pasteur Institute and listed on KOSDAQ in 2016. Specializing in pharmaceutical research and development, it possesses innovative new drug pipelines including MOCASICLIP, QP101, and AADRIXETINIB. The company prioritizes anti-cancer and autoimmune disease projects through a strategic alliance with the Max Planck Institute and pursues revenue generation by developing combination therapies with MSD's KEYTRUDA. QURIENT is headquartered in Seongnam-si, Gyeonggi-do.